Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | NEK2 | P51955 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297491 | 0.89 | BRAF (0.51) | BRAFMAP2K1NEK2CYP3A4KDR | |
| SCHEMBL298616 | 0.84 | BRAF (0.57) | BRAFMAP2K1NEK2CYP3A4KDR | |
| SCHEMBL299590 | 0.83 | BRAF (0.46) | BRAFMAP2K1NEK2CYP3A4KDR | |
| SCHEMBL298074 | 0.83 | CLK1 (0.46) | BRAFMAP2K1CYP3A4CYP2C9HTT | |
| SCHEMBL299021 | 0.82 | BRAF (0.51) | BRAFMAP2K1NEK2CYP3A4KDR | |
| SCHEMBL298469 | 0.82 | ALDH1A1 (0.47) | BRAFCYP3A4 | |
| SCHEMBL298860 | 0.81 | CYP3A4 (0.54) | BRAFMAP2K1CYP3A4KDRCYP2C9 | |
| SCHEMBL296369 | 0.81 | BRAF (0.44) | BRAFMAP2K1NEK2KDRCYP2C9 | |
| SCHEMBL855809 | 0.81 | BRAF (0.62) | BRAFMAP2K1NEK2CYP3A4KDR | |
| SCHEMBL298904 | 0.81 | CYP3A4 (0.47) | BRAFCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | BRAF 1/4885MAP2K1 131/4885NEK2 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.